Previous 10 | Next 10 |
2023-11-15 11:44:02 ET More on Markets UBS highlights 14 stocks on its list of high-conviction names Global X says AI, cybersecurity among four key themes for 2024 Cathie Wood's ARK Invest launches crypto ETFs in partnership with 21Shares Producer Price Index...
2023-11-14 19:30:27 ET Aytu BioPharma, Inc. (AYTU) Q1 2024 Earnings Conference Call November 14, 2023 04:30 PM ET Company Participants Robert Blum - IR Josh Disbrow - CEO Mark Oki - CFO Conference Call Participants Naz Rahman - Maxim Group Prese...
2023-11-14 16:28:51 ET More on Aytu BioScience Aytu BioPharma, Inc. (AYTU) Q4 2023 Earnings Call Transcript Seeking Alpha’s Quant Rating on Aytu BioScience Historical earnings data for Aytu BioScience Financial information for Aytu BioScience F...
Q1 2024 Adjusted EBITDA of $2.2 million Rx Segment net revenue of $17.8 million and Adjusted EBITDA of $2.4 million in Q1 2024 Q1 2024 ADHD net revenue up 31% compared to Q1 2023 $20.0 million cash balance at September 30, 2023 Company to host conference call today at 4:30pm E...
INVO BioScience Inc. (INVO) is expected to report for Q3 2023 HIVE Blockchain Technologies Ltd (HIVE) is expected to report $-0.13 for Q2 2024 BioNexus Gene Lab Corp (BGLC) is expected to report for Q1 2024 Adhera Therapeutics Inc (ATRX) is expected to report for Q1 2024 Altus Pow...
Ranked 118th Fastest Growing Company in North America Ranked 23rd Fastest Growing Life Sciences Company DENVER, CO / ACCESSWIRE / November 8, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today ...
DENVER, CO / ACCESSWIRE / November 7, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, will report financial results for its first quarter of fiscal year 2024 for the period ended September 30, 2023, after ...
U.S. Food & Drug Administration Approval of the Prior Approval Supplement (PAS) Enables Transfer of Cotempla Production to Contract Manufacturer Upon Completion of Manufacturing Transfer of Adzenys XR-ODT and Cotempla XR-ODT, Company Expects to Report Enhanced ADHD Product Margins DE...
ENGLEWOOD, CO / ACCESSWIRE / October 9, 2023 / Aytu BioPharma, Inc. (the Company or "Aytu") (Nasdaq:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, Chief Executive Officer, will present and host one-on-one meetings with investor...
2023-09-28 12:59:55 ET Gainers: Baudax Bio ( BXRX ) +75% . Chico's Fas ( CHS ) +63% . Aytu BioPharma ( AYTU ) +35% . Axcella Health ( AXLA ) +35% . Vaccinex ( VCNX ) +33% . Organogenesis Holdings ( ORGO ) +27% . F...
News, Short Squeeze, Breakout and More Instantly...
Company receives proceeds of $3.5 million through exercise of warrants, a portion of which was used to pay down debt Interest rate on new $13.0 million term loan reduced by approximately 350 basis points today, potentially saving the Company $1.3 million over the life of the term loan T...
Phoenix, Arizona and New York, New York--(Newsfile Corp. - May 29, 2024) - Lytham Partners, a leading investor relations and corporate access firm, today announced the schedule for its Spring 2024 Investor Conference taking place virtually on May 30, 2024. More than 40 companies will be available...
DENVER, CO / ACCESSWIRE / May 23, 2024 / Aytu BioPharma, Inc. (the Company or "Aytu") (NASDAQ:AYTU), a pharmaceutical company focused on commercializing novel therapeutics, today announced that Josh Disbrow, CEO, will participate in a webcasted fireside chat and host one-on-one meetings with inv...